Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 1;35(10):1086-1095.
doi: 10.1200/JCO.2016.71.0012. Epub 2017 Jan 30.

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer

Affiliations
Free PMC article

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer

Matthew B Yurgelun et al. J Clin Oncol. .
Free PMC article

Abstract

Purpose Hereditary factors play an important role in colorectal cancer (CRC) risk, yet the prevalence of germline cancer susceptibility gene mutations in patients with CRC unselected for high-risk features (eg, early age at diagnosis, personal/family history of cancer or polyps, tumor microsatellite instability [MSI], mismatch repair [MMR] deficiency) is unknown. Patients and Methods We recruited 1,058 participants who received CRC care in a clinic-based setting without preselection for age at diagnosis, personal/family history, or MSI/MMR results. All participants underwent germline testing for mutations in 25 genes associated with inherited cancer risk. Each gene was categorized as high penetrance or moderate penetrance on the basis of published estimates of the lifetime cancer risks conferred by pathogenic germline mutations in that gene. Results One hundred five (9.9%; 95% CI, 8.2% to 11.9%) of 1,058 participants carried one or more pathogenic mutations, including 33 (3.1%) with Lynch syndrome (LS). Twenty-eight (96.6%) of 29 available LS CRCs demonstrated abnormal MSI/MMR results. Seventy-four (7.0%) of 1,058 participants carried non-LS gene mutations, including 23 (2.2%) with mutations in high-penetrance genes (five APC, three biallelic MUTYH, 11 BRCA1/2, two PALB2, one CDKN2A, and one TP53), 15 of whom lacked clinical histories suggestive of their underlying mutation. Thirty-eight (3.6%) participants had moderate-penetrance CRC risk gene mutations (19 monoallelic MUTYH, 17 APC*I1307K, two CHEK2). Neither proband age at CRC diagnosis, family history of CRC, nor personal history of other cancers significantly predicted the presence of pathogenic mutations in non-LS genes. Conclusion Germline cancer susceptibility gene mutations are carried by 9.9% of patients with CRC. MSI/MMR testing reliably identifies LS probands, although 7.0% of patients with CRC carry non-LS mutations, including 1.0% with BRCA1/2 mutations.

Figures

Fig 1.
Fig 1.
Pathogenic mutations identified with a multigene panel among 1,058 individuals with colorectal cancer. *Includes four probands with both a high- and a moderate-penetrance mutation. †One proband carried both an MLH1 and a BRCA2 mutation. ‡Does not include the four probands with concurrent high-penetrance mutations.
Fig A1.
Fig A1.
Number of germline variants of uncertain significance (VUS), per gene, detected with a 25-gene panel in 1,058 patients with colorectal cancer.

Comment in

Similar articles

See all similar articles

Cited by 51 articles

  • Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications.
    Ye J, Lin M, Zhang C, Zhu X, Li S, Liu H, Yin J, Yu H, Zhu K. Ye J, et al. Biomed Rep. 2020 Jul;13(1):43-48. doi: 10.3892/br.2020.1303. Epub 2020 May 12. Biomed Rep. 2020. PMID: 32440349 Free PMC article.
  • Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
    Chen Z, Wang C, Dong H, Wang X, Gao F, Zhang S, Zhang X. Chen Z, et al. Mol Med. 2020 Jan 30;26(1):14. doi: 10.1186/s10020-020-0139-5. Mol Med. 2020. PMID: 32000660 Free PMC article.
  • SEOM clinical guideline on hereditary colorectal cancer (2019).
    Guillén-Ponce C, Lastra E, Lorenzo-Lorenzo I, Martín Gómez T, Morales Chamorro R, Sánchez-Heras AB, Serrano R, Soriano Rodríguez MC, Soto JL, Robles L. Guillén-Ponce C, et al. Clin Transl Oncol. 2020 Feb;22(2):201-212. doi: 10.1007/s12094-019-02272-y. Epub 2020 Jan 24. Clin Transl Oncol. 2020. PMID: 31981079
  • Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Å, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, Yoon SY, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmaña J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo SH, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M. Yang X, et al. J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907. Epub 2019 Dec 16. J Clin Oncol. 2020. PMID: 31841383
  • CDH1 on Multigene Panel Testing: Look Before You Leap.
    Katona BW, Clark DF, Domchek SM. Katona BW, et al. J Natl Cancer Inst. 2020 Apr 1;112(4):330-334. doi: 10.1093/jnci/djz229. J Natl Cancer Inst. 2020. PMID: 31841163
See all "Cited by" articles

MeSH terms

Substances

Feedback